ID
24377
Beschrijving
NCT00079911 Study ID 100181 Clinical Study ID HS2100181 Study Title: An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons with CD4+ lymphocyte count <100 cells/mm3. Patient Level Data Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00079911 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 4 Study Recruitment Status: Terminated Generic Name: valaciclovir Trade Name: ZELITREX,Valtrex,RAPIVIR,Novirus Study Indication: Genital Herpes; HIV infection
Trefwoorden
Versies (1)
- 30-07-17 30-07-17 -
Houder van rechten
GlaxoSmithKline
Geüploaded op
30 juli 2017
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
GSK Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons STATUS OF TREATMENT BLIND NCT00079911
GSK Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons STATUS OF TREATMENT BLIND NCT00079911
Similar models
GSK Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons STATUS OF TREATMENT BLIND NCT00079911
C3897431 (UMLS CUI [1,2])
C3897431 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
C0034656 (UMLS CUI [1,2])
C3897431 (UMLS CUI [1,3])
C0034656 (UMLS CUI [1,2])
C3897431 (UMLS CUI [1,3])